Insider buying last 90 days
No open-market insider purchases were filed for SMMT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SMMT insider filing, plotted on the chart in Gekko.Open SMMT in Gekko
NASDAQ: SMMT
Summit Therapeutics (SMMT) Stock Analysis & Forecast
Sep 28 close
$15.48−0.13 (−0.8%)
Gekko Brief
Summit Therapeutics closed at $15.48 on 28 September 2026, -0.8% on the day. The price sits between the 50-day ($14.85) and 200-day ($16.38) moving averages, inside a 52-week range of $12.07 to $29.23. The GekkoIndex reads 60.4, in the Accumulation zone, up 7.4 points over five sessions. Gekko Fair Value is $18.69, so the price is 17.2% below it.
The next earnings report is due on 19 October 2026, 20 days away. Over the last 8 reports the company beat the earnings estimate 2 times, with an average move of 12.6% across the report. Seasonally, the next 20 trading days from this point averaged -7.5% over the last 5 years, rising in 1 of them.
14 firms rate the stock: 9 buy, 5 hold and 0 sell, with a consensus target of $28.58. A typical daily move is about 6.1%, and a typical 20-day move about 15%. On the swing-trade checklist, 2 items read supportive and 2 read as a headwind (earnings risk, seasonality).
Generated Sep 29, 2026 from the data above.
Summit Therapeutics price vs fair value
Close $15.48200-day averageGekko Fair Value $18.69
Summit Therapeutics quick facts
- Market cap
- $12.35B
- P/E ratio
- —
- Forward P/E
- 3.7
- EPS, TTM
- −$1.11
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -1.24
- Volume
- 4.34M avg 6.02M
- 1-year return
- −23.6%
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±15%
- 50-day average
- $14.85
- 200-day average
- $16.38
- Next earnings
- Oct 19
- Shares outstanding
- 797.8M
Summit Therapeutics swing-trade checklist
Summit Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $15.48 sits between the 50-day ($14.85) and 200-day ($16.38) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.4, Accumulation
Reading 60.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
17.2% below
Price is 17.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 20 days
Reports on Oct 19, 2026, 20 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−7.5% on average
From this point in the calendar, the next 20 trading days averaged −7.5% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Summit Therapeutics stock chart and price history
Summit Therapeutics closed at $15.48 on Sep 28, 2026, −23.6% over the past year, inside a 52-week range of $12.07 to $29.23.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.0%
- 3 months
- +8.1%
- 6 months
- −6.6%
- 1 year
- −23.6%
The full SMMT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SMMT in Gekko
Follow Summit Therapeutics through every session
Put SMMT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SMMT in GekkoFree for 7 days. No credit card required.
About Summit Therapeutics
Summit Therapeutics works in biopharmaceutical research, focused on finding, developing, and bringing to market treatments for infectious diseases in the United States and Latin America. Much of its pipeline centers on Clostridioides difficile infection, or CDI, with an oral small-molecule antibiotic called ridinilazole as its most advanced candidate, now in Phase III trials for that condition.
Alongside ridinilazole, the company is advancing SMT-738, aimed at multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and a group of compounds known as DDS-04, which target various infections caused by Enterobacteriaceae bacteria. Its work is organized around this pipeline of infectious-disease therapies rather than a marketed product line.
Summit Therapeutics was founded in 2003 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker SMMT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- smmttx.com
Summit Therapeutics GekkoIndex: the smart money zone
Summit Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.4, in the Accumulation zone, up 7.4 points over five sessions.
60.4Accumulation
Up 7.4 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +25.7% | +36.3% | ||
| Accumulation (current zone) | 232 | +2.7% | +5.9% | ||
| Neutral | 390 | +2.0% | +8.9% | ||
| Distribution | 27 | −4.9% | −14.6% | ||
| Selling | 4 | Too few readings yet | |||
Average SMMT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SMMT price, zone by zone.Track SMMT in Gekko
Is Summit Therapeutics stock overvalued? Gekko Fair Value
Summit Therapeutics trades 17.2% below Gekko Fair Value of $18.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Summit Therapeutics shares are worth, recalculated every trading day.
$18.69
Gekko Fair Value, Sep 26, 2026
17.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SMMT in Gekko
Summit Therapeutics insider and Congress trading
No open-market insider purchases were filed for Summit Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SMMT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SMMT, plotted on the chart in Gekko.Open SMMT in Gekko
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds SMMT.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Summit Therapeutics earnings: next date and track record
Summit Therapeutics reports on Oct 19, 2026 (20 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Oct 19, 2026
20 days away
- EPS estimate
- −$0.28
- Revenue estimate
- $71K
2 of 8reports beat the EPS estimate
±12.6%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- Summit Therapeutics reported Q2 2026 results highlighting ivonescimab's strong clinical momentum with 4 positive Phase III readouts, 2 China approvals, and a pending FDA BLA decision expected late 2026. Over 70,000 patients have been treated commercially in China. The company has 15 Phase III trials ongoing across multiple tumor types and 52 total clinical trials initiated with partner Akeso. An updated OS analysis for the HARMONi trial was recently announced.
- Guidance
- Summit anticipates an FDA BLA decision on ivonescimab towards end of 2026 and is actively preparing for commercialization. Management is expanding clinical development plans across multiple solid tumor indications while pursuing combination therapy partnerships with large pharma.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | −$0.28 est −$0.26 | — est $114K | −7.3% |
| Apr 30, 2026 | −$0.18 est −$0.12 | — est $54K | −22.7% |
| Feb 23, 2026 | −$0.29 est −$0.10 | — est $56.78M | +1.1% |
| Oct 20, 2025 | −$0.23 est −$0.10 | — est $76.50M | −10.7% |
| Aug 11, 2025 | −$0.76 est −$0.09 | — | −10.4% |
| May 1, 2025 | −$0.07 est −$0.07 | — | +15.7% |
| Feb 24, 2025 | −$0.07 est −$0.08 | — | −18.1% |
| Oct 30, 2024 | −$0.08 est −$0.07 | — | −14.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Summit Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Summit Therapeutics is $28.58, +84.6% from the last close, from 14 firms rating the stock in the last 90 days.
$28.58consensus 12-month target, +84.6% from the last close
Now $15.48Avg $28.58
Low $11.90High $41
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Piper Sandler | $16 | +3.4% |
| Sep 25 | Bernstein | $11.90 | −23.1% |
| Sep 23 | H.C. Wainwright | — | — |
| Sep 21 | Barclays | $18 | +16.3% |
| Sep 13 | UBS | $33 | +113.2% |
+5.9%average 20-day move after past Accumulation readings
−7.5%average move over the next 20 trading days in the last 5 years
±6.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Summit Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Summit Therapeutics averaged −7.5% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.7% | 1 of 5 |
| Next 10 trading days | −5.3% | 1 of 5 |
| Next 15 trading days | +2.3% | 4 of 5 |
| Next 20 trading days | −7.5% | 1 of 5 |
| Next 30 trading days | −5.1% | 2 of 5 |
For scale, SMMT’s typical 20-trading-day move in either direction is about 15%.
Summit Therapeutics market cap and key statistics
Summit Therapeutics’s market cap is $12.35B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $12.35B
- Forward P/E
- 3.7
- EPS, TTM
- −$1.11
- Gekko Fair Value
- $18.69
Trading
- Volume
- 4.34M
- Avg volume, 20 days
- 6.02M
- 52-week high
- $29.23
- 52-week low
- $12.07
- Shares outstanding
- 797.8M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -192.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -1.24
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±15%
Summit Therapeutics stock news this week
3 headlines about Summit Therapeutics from the past week, newest first, each linking to the publisher.
Summit Therapeutics peers
Summit Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Summit Therapeutics stock FAQ
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $12.35B at the Sep 28, 2026 close of $15.48, with 797.8M shares outstanding.
What is the Summit Therapeutics stock forecast?
The consensus analyst 12-month price target for Summit Therapeutics is $28.58, +84.6% from the last close. Of the 14 firms that rated the stock in the last 90 days, 9 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Summit Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Summit Therapeutics is undervalued: the Sep 28, 2026 close of $15.48 is 17.2% below Gekko Fair Value of $18.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Summit Therapeutics report earnings next?
Summit Therapeutics is expected to report on Oct 19, 2026 (20 days away). Analysts expect earnings of −$0.28 per share on revenue of $71K. Summit Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 12.6% on average across the report.
What is Summit Therapeutics’s 52-week high and low?
Summit Therapeutics’s 52-week high is $29.23 and its 52-week low is $12.07; it closed at $15.48 on Sep 28, 2026, −23.6% over the past year. Over the last five years the shares peaked at $36.91 on Apr 24, 2025.
Is Summit Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Summit Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.